-
公开(公告)号：US07566704B2
公开(公告)日：2009-07-28
申请号：US11333765
申请日：2006-01-17
IPC分类号： A61K31/715 , A61K47/00 , C07H1/00
CPC分类号： A61K31/716 , C08B37/0024 , C08L5/00 , Y10S514/885 , Y10S514/944 , Y10S514/951 , Y10S514/959 , Y10S514/962
摘要： The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble β-glucan composition comprising β-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).
-
公开(公告)号：US07022685B2
公开(公告)日：2006-04-04
申请号：US10094686
申请日：2002-03-07
IPC分类号： A61K31/715 , C07H1/00 , A01N25/00
CPC分类号： A61K31/716 , C08B37/0024 , C08L5/00 , Y10S514/885 , Y10S514/944 , Y10S514/951 , Y10S514/959 , Y10S514/962
摘要： The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble β-glucan composition comprising β-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).
-
公开(公告)号：US5633369A
公开(公告)日：1997-05-27
申请号：US464528
申请日：1995-06-05
IPC分类号： A61K31/715 , A61K31/716 , C08B37/00 , C12P19/04 , C07H1/00 , C07H1/06
CPC分类号： A61K31/716 , A61K31/715 , C08B37/0024 , C12P19/04
摘要： A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.
摘要翻译： 公开了一种生产中性葡聚糖聚合物的可溶性制剂的方法。 该方法包括用独特的酸和碱处理序列处理全葡聚糖颗粒以产生可溶性葡聚糖。 可溶性葡聚糖可以纯化得到中性葡聚糖分子的生理上可接受的溶液。 获得可溶性中性葡聚糖制剂，其在中性pH下形成澄清溶液，并在药学上可接受的载体中平衡。
-
公开(公告)号：US06369216B1
公开(公告)日：2002-04-09
申请号：US09325152
申请日：1999-06-03
IPC分类号： A61K31715
CPC分类号： C08B37/0024
摘要： The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble &bgr;-glucan composition comprising &bgr;-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).
摘要翻译： 本发明涉及用于通过施用包含平均分子量至少为1,000,000道尔顿的β-葡聚糖分子的可溶性β-葡聚糖组合物来治疗/预防动物或人类感染的组合物和治疗和预防方法，如多角度 激光散射（VHMW-葡聚糖）。
-
5.发明授权
公开(公告)号：US5488040A
公开(公告)日：1996-01-30
申请号：US60418
申请日：1993-05-11
IPC分类号： A61K31/715 , A61K31/716 , C08B37/00 , C12P19/04 , C07H1/00 , C07H3/00
CPC分类号： A61K31/716 , A61K31/715 , C08B37/0024 , C12P19/04
摘要： The present invention relates to neutral soluble .beta.-glucans which exert potent and specific hematopoietic and immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral soluble glucan preparation has a high affinity for the .beta.-glucan receptor of human mono-cytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte and neutrophil hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral soluble glucan of this invention neither induces nor primes IL-1 and TNF production in vitro and in vivo. Safe and efficacious preparations of neutral soluble glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1, TNF and leukotrienes) that can cause detrimental side effects, such as fever and inflammation.
摘要翻译： 本发明涉及在不刺激某些细胞因子产生的情况下发挥有效和特异性的造血和免疫学作用的中性可溶性β-葡聚糖，含有新型β-葡聚糖的制剂及其制造方法。 中性可溶性葡聚糖制剂对人单核细胞的β-葡聚糖受体具有高亲和力，并保留两种主要的生物（或免疫）活性，（1）增强吞噬细胞的杀微生物活性，和（2）单核细胞和嗜中性粒细胞 造血活性。 与现有技术中描述的可溶性葡聚糖不同，本发明的中性可溶性葡聚糖在体外和体内都不诱导或引发IL-1和TNF产生。 本发明的中性可溶性葡聚糖的安全有效的制剂可用于人和动物的治疗和/或预防性治疗方案中，以增强其免疫应答，而不刺激某些生物化学介质（例如IL-1，TNF和 白细胞三烯），其可引起有害的副作用，例如发烧和炎症。
-
公开(公告)号：US5322841A
公开(公告)日：1994-06-21
申请号：US970547
申请日：1992-11-02
IPC分类号： A61K31/715 , A61K31/716 , A61P37/04 , C08B37/00 , C12P19/04
CPC分类号： A61K31/716 , A61K31/715 , C08B37/0024 , C12P19/04 , Y10S514/885
摘要： A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence or acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.
摘要翻译： 公开了一种生产中性葡聚糖聚合物的可溶性制剂的方法。 该方法包括以独特的顺序或酸和碱处理来处理全葡聚糖颗粒以产生可溶性葡聚糖。 可溶性葡聚糖可以纯化得到中性葡聚糖分子的生理上可接受的溶液。 获得可溶性中性葡聚糖制剂，其在中性pH下形成澄清溶液，并在药学上可接受的载体中平衡。
-
公开(公告)号：US5032401A
公开(公告)日：1991-07-16
申请号：US366490
申请日：1989-06-15
CPC分类号： A61K9/5068 , A61K39/39 , A61K9/1652 , A61K2039/55555 , A61K2039/55583 , Y10S514/885 , Y10S530/817
摘要： The invention describes a whole .beta.-glucan drug delivery vehicle that non-specifically enhances the immune response, and is safe for human use. A drug is incorporated into a whole .beta.-glucan microparticle, and the combination is administered to an individual. The .beta.-glucan vehicle allows sustained release of the drug component while simultaneously enhancing the effectiveness of the drug by boosting the individual's endogenous immune response.
摘要翻译： 本发明描述了一种非特异性增强免疫应答的全β-葡聚糖药物递送载体，并且对人类来说是安全的。 将药物并入整个β-葡聚糖微粒中，并将该组合施用于个体。 β-葡聚糖载体允许药物组分的持续释放，同时通过增强个体的内源性免疫应答来提高药物的有效性。
-
8.发明授权Underivatized, aqueous soluable .beta.(1-3) glucan, composition and method of making same 失效未完全溶解的水溶性β（1-3）葡聚糖，其组成和制备方法
公开(公告)号：US5817643A
公开(公告)日：1998-10-06
申请号：US469233
申请日：1995-06-06
IPC分类号： A61K9/08 , A61K31/715 , A61K31/716 , A61K36/06 , A61P7/00 , A61P17/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P37/00 , A61P37/04 , A61P43/00 , C08B37/00 , C07H1/00 , C07H3/00
CPC分类号： A61K31/715 , C08B37/0024
摘要： The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucan receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucan of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.-glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1.beta., TNF.alpha.) that can cause detrimental side effects, such as fever and inflammation.
摘要翻译： 本发明涉及在不刺激某些细胞因子的产生的情况下发挥有效和特异性的免疫学作用的中性水溶性β-葡聚糖，含有新型β-葡聚糖的制剂，以及其新颖的制造方法。 中性水溶性β-葡聚糖制剂对人单核细胞的β-葡聚糖受体具有高亲和力，并保留两种主要的生物（或免疫）活性，（1）增强吞噬细胞的杀微生物活性，和（2）单核细胞 ，嗜中性粒细胞和血小板造血活性。 与现有技术中描述的可溶性葡聚糖不同，本发明的中性水溶性β-葡聚糖在体外和体内都不诱导或引发IL-1β和TNFα产生。 本发明的中性水溶性β-葡聚糖的安全有效的制剂可用于人和动物的治疗和/或预防性治疗方案以增强其免疫应答，而不刺激某些生物化学介质（例如IL- 1β，TNFα），可引起不良副作用，如发烧和炎症。
-
公开(公告)号：US5811542A
公开(公告)日：1998-09-22
申请号：US432303
申请日：1995-05-02
IPC分类号： A61K31/715 , A61K31/716 , C08B37/00 , C12P19/04 , C07H1/00
CPC分类号： A61K31/716 , A61K31/715 , C08B37/0024 , C12P19/04
摘要： A method for producing soluble preparations of neutral glucan polymers is disclosed. The method involves treating whole glucan particles with a unique sequence of acid and alkaline treatments to produce soluble glucan. The soluble glucan can be purified to obtain a physiologically acceptable solution of neutral glucan molecules. A soluble neutral glucan preparation is obtained which forms a clear solution at a neutral pH and is equilibrated in a pharmaceutically acceptable carrier.
摘要翻译： 公开了一种生产中性葡聚糖聚合物的可溶性制剂的方法。 该方法包括用独特的酸和碱处理序列处理全葡聚糖颗粒以产生可溶性葡聚糖。 可溶性葡聚糖可以纯化得到中性葡聚糖分子的生理上可接受的溶液。 得到可溶性中性葡聚糖制剂，其在中性pH下形成澄清溶液，并在药学上可接受的载体中平衡。
-
10.发明授权Uses for underivatized, aqueous soluble .beta.(1-3) glucan and compositions comprising same 失效用于未衍生的水溶性β（1-3）葡聚糖及其组合物
公开(公告)号：US5783569A
公开(公告)日：1998-07-21
申请号：US373251
申请日：1995-01-26
IPC分类号： A61K9/08 , A61K31/715 , A61K31/716 , A61K36/06 , A61P7/00 , A61P17/02 , A61P31/00 , A61P31/04 , A61P31/12 , A61P37/00 , A61P37/04 , A61P43/00 , C08B37/00 , C07H1/00
CPC分类号： A61K31/715 , C08B37/0024
摘要： The present invention relates to neutral, aqueous soluble .beta.-glucans which exert potent and specific immunological effects without stimulating the production of certain cytokines, to preparations containing the novel .beta.-glucans, and to a novel manufacturing process therefor. The neutral, aqueous soluble .beta.-glucan preparation has a high affinity for the .beta.-glucans receptor of human monocytes and retains two primary biological (or immunological) activities, (1) the enhancement of microbicidal activity of phagocytic cells, and (2) monocyte, neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral, aqueous soluble .beta.-glucans of this invention neither induces nor primes IL-1.beta. and TNF.alpha. production in vitro and in vivo. Safe and efficacious preparations of neutral, aqueous soluble .beta.-glucan of the present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g., IL-1.beta., TNF.alpha.) that can cause detrimental side effects, such as fever and inflammation.
摘要翻译： PCT No.PCT / US93 / 07904 Sec。 371日期1995年1月26日 102（e）日期1995年1月26日PCT提交1993年8月20日PCT公布。 公开号WO94 / 04163 日期1994年3月3日本发明涉及在不刺激某些细胞因子的产生的情况下发挥有效和特异性的免疫学效果的中性水溶性β-葡聚糖，涉及含有新型β-葡聚糖的制剂，以及其新颖的制造方法。 中性水溶性β-葡聚糖制剂对人单核细胞的β-葡聚糖受体具有高亲和力，并保留两种主要的生物（或免疫）活性，（1）增强吞噬细胞的杀微生物活性，和（2）单核细胞 ，嗜中性粒细胞和血小板造血活性。 与现有技术中描述的可溶性葡聚糖不同，本发明的中性水溶性β-葡聚糖在体外和体内都不诱导或引发IL-1β和TNFα产生。 本发明的中性水溶性β-葡聚糖的安全有效的制剂可用于人和动物的治疗和/或预防性治疗方案以增强其免疫应答，而不刺激某些生物化学介质（例如IL- 1β，TNFα），可引起不良副作用，如发烧和炎症。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.021 秒)
